Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H1 2012

Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H1 2012', provides an overview of the Adrenocortical Carcinoma (Adrenal Cortex Cancer) therapeutic pipeline. This report provides information on the therapeutic development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Adrenocortical Carcinoma (Adrenal Cortex Cancer). 'Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Adrenocortical Carcinoma (Adrenal Cortex Cancer).
- A review of the Adrenocortical Carcinoma (Adrenal Cortex Cancer) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Adrenocortical Carcinoma (Adrenal Cortex Cancer) pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Adrenocortical Carcinoma (Adrenal Cortex Cancer).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Adrenocortical Carcinoma (Adrenal Cortex Cancer) pipeline depth and focus of Adrenocortical Carcinoma (Adrenal Cortex Cancer) therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Adrenocortical Carcinoma (Adrenal Cortex Cancer) Therapeutic Products under Development, Key Players in Adrenocortical Carcinoma (Adrenal Cortex Cancer) Therapeutics, Adrenocortical Carcinoma (Adrenal Cortex Cancer) Pipeline Overview, Adrenocortical Carcinoma (Adrenal Cortex Cancer) Pipeline, Adrenocortical Carcinoma (Adrenal Cortex Cancer) Pipeline Assessment SHOW LESS READ MORE >

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Adrenocortical Carcinoma (Adrenal Cortex Cancer) Overview
Therapeutics Development
An Overview of Pipeline Products for Adrenocortical Carcinoma (Adrenal Cortex Cancer)
Adrenocortical Carcinoma (Adrenal Cortex Cancer) Therapeutics under Development by Companies
Adrenocortical Carcinoma (Adrenal Cortex Cancer) Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Adrenocortical Carcinoma (Adrenal Cortex Cancer) Therapeutics – Products under Development by Companies
Adrenocortical Carcinoma (Adrenal Cortex Cancer) Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Adrenocortical Carcinoma (Adrenal Cortex Cancer) Therapeutics Development
OSI Pharmaceuticals, Inc.
Pfizer Inc.
Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Inlyta - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OSI-906 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Seneca Valley Virus-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mitotane - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Etoposide + Doxorubicin + Cisplatin + Mitotane - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Streptozocin + Mitotane - Drug Profile
Product Description
Mechanism of Action
R&D Progress
G-CSF + Pegfilgrastim + Cisplatin + Doxorubicin + Etoposide + Mitotane - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Doxorubicin + Vincristine + Etoposide + Mitotane - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mitotane + Cixutumumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Etoposide + Doxorubicin + Cisplatin + Mitotane - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Streptozotocin + Mitotane - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sunitinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatin + Taxotere - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AT-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IMC-A12 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + Capecitabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + Metronomic 5-Fluorouracil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Adrenocortical Carcinoma (Adrenal Cortex Cancer) Therapeutics – Drug Profile Updates
Adrenocortical Carcinoma (Adrenal Cortex Cancer) Therapeutics – Discontinued Products
Adrenocortical Carcinoma (Adrenal Cortex Cancer) Therapeutics - Dormant Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), H1 2012
Products under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
OSI Pharmaceuticals, Inc., H1 2012
Pfizer Inc., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Adrenocortical Carcinoma (Adrenal Cortex Cancer) Therapeutics – Drug Profile Updates
Adrenocortical Carcinoma (Adrenal Cortex Cancer) Therapeutics – Discontinued Products
Adrenocortical Carcinoma (Adrenal Cortex Cancer) Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), H1 2012
Products under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012